MENTOR heralds a new era of therapy for membranous nephropathy
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Nephrology"
DOI: 10.1038/s41581-019-0200-1
Abstract: The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up to 40% of patients did… read more here.
Keywords: mentor; mentor heralds; heralds new; membranous nephropathy ... See more keywords